XORTX Therapeutics Inc.
No SEC Form 4 filings for $XRTX in the last 30 days.
See all $XRTX insider activity →XORTX Therapeutics (NASDAQ: XRTX) has begun manufacturing GMP drug substance and commercial-scale tablets for its XORLO™ gout treatment. This supports the planned XRX-OXY-102 clinical study and future FDA marketing approval. The company aims to address unmet needs in gout treatment with its proprietary oxypurinol formulation.
XORTX Therapeutics Inc. (NASDAQ: XRTX, TSXV: XRTX) said director Anthony Giovinazzo will resign from its board for personal reasons. The company thanked him for his multi-year role as board chairman and work on key committees. XORTX also reiterated its late-stage gout and kidney disease drug development pipeline.
XORTX Therapeutics Inc. (NASDAQ: XRTX, TSXV: XRTX) said it appointed Depesh Narotam as an independent director effective July 27, 2026. He will sit on the Compensation, Governance and Nominating Committee. The company also outlined its late-stage pipeline for gout and kidney disease, including XRx-026, XRx-008, and XRx-101.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning XRTX (XORTX Therapeutics Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Initiation of manufacturing supports the upcoming XRX-OXY-102 trial and future NDA filing, reducing supply risk.
Board leadership change may affect governance optics and committee continuity, but the release provides no operational or financial guidance changes.
Board refresh is unlikely to change near-term fundamentals, but it can modestly affect governance expectations and committee oversight.
TSXV delisting should reduce ongoing listing/admin costs and regulatory complexity, with limited direct fundamental change; near-term trading may reflect liquidity/venue-shift effects.
The company's planned US$5 million share offering at US$1.88 per share has led to a sharp 23.20% decline in stock price, indicating negative market sentiment. This event may exert downward pressure on the stock in the short term, with potential for rebound if the offering proceeds smoothly and investor confidence is restored.
AlphAI scores every news story that mentions XRTX with an AI model for sentiment and relevance, and aggregates insider trades from XORTX Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
XORTX Therapeutics (NASDAQ: XRTX) has begun manufacturing GMP drug substance and commercial-scale tablets for its XORLO™ gout treatment. This supports the planned XRX-OXY-102 clinical study and future FDA marketing approval. The company aims to address unmet needs in gout treatment with its proprietary oxypurinol formulation.
2 min readXORTX Therapeutics Inc. (NASDAQ: XRTX, TSXV: XRTX) said director Anthony Giovinazzo will resign from its board for personal reasons. The company thanked him for his multi-year role as board chairman and work on key committees. XORTX also reiterated its late-stage gout and kidney disease drug development pipeline.
2 min readXORTX Therapeutics Inc. (NASDAQ: XRTX, TSXV: XRTX) said it appointed Depesh Narotam as an independent director effective July 27, 2026. He will sit on the Compensation, Governance and Nominating Committee. The company also outlined its late-stage pipeline for gout and kidney disease, including XRx-026, XRx-008, and XRx-101.
2 min readXORTX Therapeutics Inc. (NASDAQ: XRTX; TSXV: XRTX) said it has elected to voluntarily delist its common shares from the TSX Venture Exchange. The company cited costs and administrative burden from maintaining a dual listing and differences in regulatory environments. It expects no shareholder action; Canadian shareholders will still trade on Nasdaq.
2 min readXORTX Therapeutics has priced a public offering of 2,659,574 common shares or pre-funded warrants at US$1.88 per share, aiming to raise US$5 million in gross proceeds. The offering is expected to close around May 15, 2026, subject to regulatory approvals. Following this announcement, XRTX's stock experienced a significant negative market reaction, declining by 23.20%.
2 min readXORTX Therapeutics Inc. filed an EFFECT Form with the SEC, which became effective on May 13, 2026. This filing, with accession number 0001104659-26-057834, is a POS AM submission indicating a post-effective amendment. The company, trading under NASDAQ: XRTX, has a market cap of $3.76 million and is involved in biotechnology.
2 min readXORTX Therapeutics (XRTX) significantly reduced its net loss to US$2.66 million in 2025 due to progress in late-stage clinical programs for gout and kidney diseases, with a New Drug Application (NDA) filing targeted within 12 months. Despite this financial improvement, the company's cash reserves dwindled, emphasizing the need for critical ongoing funding to manage regulatory and market risks. This information is derived from an AI-generated summary of their SEC 20-F Annual Report.
4 min readCALGARY, Alberta, Oct. 20, 2025 ( GLOBE NEWSWIRE ) -- XORTX Therapeutics Inc. ( "XORTX" or the "Company" ) ( NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU ) , a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, ...
2 min readCALGARY, Alberta, Oct. 20, 2025 ( GLOBE NEWSWIRE ) -- XORTX Therapeutics Inc. ( "XORTX" or the "Company" ) ( NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU ) , a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, ...
2 min readCALGARY, Alberta, Oct. 17, 2025 ( GLOBE NEWSWIRE ) -- XORTX Therapeutics Inc. ( "XORTX" or the "Company" ) ( NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU ) ) , a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, ...
2 min read
